A newly approved drug, sotagliflozin, has shown significant benefits in reducing heart attacks and strokes for people with type 2 diabetes and kidney disease. A study published in The Lancet Diabetes & Endocrinology highlights the drugās unique cardiovascular advantages, making it a promising new option for patients with chronic conditions.
Sotagliflozinās Breakthrough Benefits
Sotagliflozin, commercially sold as Inpefa, is the first drug of its kind to offer these cardiovascular benefits. It belongs to the sodium-glucose cotransporter (SGLT) inhibitor family. Unlike other SGLT2 inhibitors, it blocks both SGLT1 and SGLT2 proteins. These proteins help move glucose and sodium across cell membranes, assisting in blood sugar regulation.
The drug is especially effective in reducing heart attacks and strokes. Researchers noted it provides a significant reduction in myocardial infarction (heart attacks) and stroke, which has not been observed in trials of other SGLT2 inhibitors.
Read:Ā Fei-Fei Li Urges Policymakers to Avoid Sci-Fi Hype in AI
Study Findings
The study followed over 10,000 patients with type 2 diabetes, chronic kidney disease, and cardiovascular risk factors. Participants were randomly assigned either sotagliflozin or a placebo and monitored for an average of 16 months.
Dr. Deepak L. Bhatt, study chair and director at Mount Sinai Fuster Heart Hospital, explained that the dual blockade of SGLT1 and SGLT2 receptors was key to the drugās success. SGLT1 receptors are located in the kidney, gut, heart, and brain, while SGLT2 receptors are found in the kidney. Blocking both receptors helps reduce cardiovascular risks more effectively.
How Sotagliflozin Differs from Other Drugs
Ā These findings may encourage more widespread use of the drug, especially for patients at high cardiovascular risk.
Addressing Multiple Health Risks
If launched successfully, sotagliflozin could tackle multiple chronic conditions. Physicians now have a new option to reduce the risk of heart failure, kidney disease progression, heart attacks, and strokes in patients with type 2 diabetes, chronic kidney disease, or heart failure.
These new data show that it also reduces heart attacks and strokes, making it even more valuable for high-risk patients.ā
Follow us onĀ Google News,Ā Instagram,Ā YouTube,Ā Facebook,Whats App, andĀ TikTokĀ for latest updates
